Raymond James raises Fulgent Genetics stock price target to $36 on strong performance
Investing.com - Bernstein SocGen Group lowered its price target on Cigna (NYSE:CI) to $294.00 from $346.00 on Wednesday, while maintaining a Market Perform rating on the health insurance company. The new target represents a modest 10% upside from Cigna’s current trading price of $268, though InvestingPro data suggests the stock may be significantly undervalued based on its Fair Value assessment.
The firm cited Cigna’s new pharmacy benefit manager (PBM) model as "more sustainable," but indicated it was "not expecting valuation rerating yet" following the company’s third-quarter earnings report.
Cigna reported adjusted earnings per share of $7.83 for the third quarter of 2025, exceeding consensus estimates by 2.5%, while revenue reached $69.57 billion, surpassing expectations by 3.2%.
The company’s medical loss ratio (MLR) came in at 84.8%, which was 36 basis points below consensus but 200 basis points higher than the same quarter in 2024, with the increase attributed to higher stop loss medical costs and pressure in the Individual and Family Plans business.
Cigna reaffirmed its full-year 2025 earnings guidance of at least $29.60 per share, with adjusted operating income targets of at least $7,200 million for Evernorth and at least $4,125 million for Cigna Healthcare.
In other recent news, Cigna reported strong financial results for the third quarter of 2025, with adjusted earnings per share (EPS) of $7.83, surpassing analyst expectations of $7.64. The company’s revenue also exceeded forecasts, reaching $69.7 billion compared to the anticipated $67.61 billion. Despite these positive earnings, several analyst firms have adjusted their price targets for Cigna. TD Cowen lowered its target to $333 while maintaining a Buy rating, and Raymond James reduced its target to $350, keeping a Strong Buy rating. Jefferies also decreased its price target to $310, citing higher-than-expected costs related to Cigna’s pharmacy benefit management model transition. Additionally, Cigna announced the appointment of Dr. Amy Flaster as Chief Medical Officer, effective November 1. Dr. Flaster will lead efforts to enhance clinical excellence and introduce new care models. These developments are part of Cigna’s ongoing strategy to strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.